Description
NLG919 is an inhibitor of indoleamine-2,3-dioxygenase (IDO). This compound displays anticancer chemotherapeutic activity, prolonging survival rates in animal models of glioblastoma.
Product Unit Size | Cost | Quantity | Stock |
---|
NLG919 is an inhibitor of indoleamine-2,3-dioxygenase (IDO). This compound displays anticancer chemotherapeutic activity, prolonging survival rates in animal models of glioblastoma.
Cas No. | 1402836-58-1 |
---|---|
Purity | ≥98% |
Formula | C18H22N2O |
Formula Wt. | 282.39 |
Chemical Name | 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol |
IUPAC Name | 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol |
Synonym | NLG919 (GDC-0919), GTPL9019 |
Solubility | Ethanol 30 mg/mL (106.23 mM) DMSO 15 mg/mL warmed (53.11 mM) Water Insoluble |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2014 Dec 15;3(10):e957994. PMID: 25941578.
Li M, Bolduc AR, Hoda MN, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21. PMID: 25054064.
Heterocyclic light-emitting compound, natural l...
Glucocorticoid agonist.
Endogenous glycoprotein hormone involved in red...
Methylated derivative of n-octyl-caffeate.
p110δ PI3K inhibitor.
NMDA partial agonist, D-Ala-D-Ala ligase inhibi...
Thymidylate synthase inhibitor, potential SHMT,...
PLK1 inhibitor.
Aspirin analog; hemoglobin chain cross-linker.<...
Lipopeptide; 1,3-β-Glucan synthase inhibitor.<...
Antineoplastic immunomodulator.
Pneumonia antigen
Triterpene saponin found in species of Panax. <...
Lignan found in species of Magnolia; GABA-A pot...
Mycotoxin produced by species of Aspergillus; D...
Selective inhibitor of LRRK2.
MET inhibitor.
NSAID; COX-1/2 inhibitor.
Fluoroquinolone; bacterial DNA gyrase inhibitor...